GSK Joins PRECISE–SG100K PCC as 5th Pharma Partner
GSK’s participation in the PRECISE–SG100K Pharma Pre Competitive Consortium (PCC) reflects growing industry recognition of Singapore’s National Precision Medicine (NPM) and the PRECISE- SG100K project, as a strategic platform for collaboration in advancing national population health and strengthening Singapore’s position as a trusted hub for precision medicine research in Asia.
-
GSK joins as the newest member of PRECISE-SG100K PCC, alongside Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk.
-
As Asia’s first pharma pre-competitive consortium of its kind, the collaboration positions Singapore as a convening centre for global pharmaceutical partners to collaborate on translational research, strengthening precision medicine capabilities in the region.
-
GSK brings deep expertise and end-to-end R&D capabilities on understanding of human biology, the science of the immune system and clinical development, complementing PRECISE-SG100K’s large-scale multi-ancestry dataset and strengthening research focused on Asian populations.
SINGAPORE, 5 MAY 2026 - Precision Health Research, Singapore (PRECISE) today announced that GSK has joined the PRECISE-SG100K Pharma Pre-competitive Consortium, becoming the fifth global pharmaceutical company to participate in this collaboration, anchored on the PRECISE-SG100K dataset.
The growing Consortium also includes Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk. Built on the PRECISE-SG100K dataset, GSK's participation underscores the growing strategic importance of Asian genomic data. Under the Consortium, GSK will access and analyse the PRECISE-SG100K dataset within a secure research environment. By expanding analyses in Asian cohorts, this collaboration aims to generate new insights into disease biology, risk factors and treatment response relevant to Asian populations, while contributing to global research diversity.
“We are pleased to welcome GSK to the Consortium. Their expertise in leveraging human genetics and biobank-based research for drug discovery will strengthen our collective knowledge base and enrich the scientific value of this collaboration. GSK’s participation reflects continued industry interest in the research value of the PRECISE-SG100K data resource,” said Prof. John Chambers, Chief Scientific Officer, PRECISE and lead PI of PRECISE-SG100K cohort.
GSK brings together science, technology and clinical expertise to provide a deep understanding of human biology to accelerate the discovery, development and delivery of medicines and vaccines to positively impact people’s health. This aligns naturally with the NPM programme and PRECISE-SG100K cohort's objectives. Its long-standing presence in Singapore's commercial, manufacturing and research landscape means this is not a distant partnership. GSK is firmly embedded in the health and biomedical ecosystem that the NPM programme is deeply integrated in, making this partnership a natural extension of the shared vision across Singapore's precision medicine landscape.
“This collaboration reflects a shared commitment to advancing precision medicine research in a careful and systematic way. By enabling secure and governed access to the PRECISE-SG100K dataset and working with partners across the ecosystem, we can generate evidence on how genetic, clinical and lifestyle factors interact in Asian populations, and support research into disease risk, progression and treatment response over time,” said Prof Patrick Tan, Executive Director, PRECISE.
“This is a pivotal step in generating Asian-specific genomic insights and R&D partnership in Singapore for GSK. Through the high-quality PRECISE-SG100K dataset, combined with other global datasets, we are continuing to deepen our understanding of human biology and disease and to translate those insights to discover, develop and deliver new medicines for patients in the region and around the world,” said Robert Scott, Vice President of R&D Translational Sciences at GSK.
“The exciting partnership of GSK with PRECISE marks a significant milestone in GSK’s journey of advancing R&D in Asia, leveraging the strength of Singapore in global healthcare innovation and driving continued development of local ecosystems and talent growth,” said Beulah Ji, Vice President, Head of GSK Asia R&D.
GSK's addition to the Pre-Competitive Consortium will deepen collaboration between academia, healthcare and industry, strengthening Singapore's biomedical ecosystem through enhanced data science capabilities, translational research support, and knowledge transfer and workforce development.
